Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T‐ALL‐iPSC in vivo

Weiran Li, Meiling Zhou, Lu Wang, Liying Huang, Xuemei Chen, Xizhuo Sun, Tao LiuCancer 2023 · DOI

TL;DR

This study explores a novel immunotherapy approach for T-cell acute lymphoblastic leukemia (T-ALL) by using induced pluripotent stem cells (iPSCs) derived from T-ALL cells as a source of tumor antigens. The research demonstrates that T cells, primed with these T-ALL-iPSC antigens, can effectively inhibit tumor growth in mice without causing significant acute or long-term toxicity, suggesting a promising new avenue for leukemia treatment.

What Problem Does This Paper Address?

Acute lymphoblastic leukemia (ALL), particularly the T-cell subtype (T-ALL), remains a significant clinical challenge due to recurrence and drug resistance. While adoptive T cell immunotherapy has shown promise, limitations like the heterogeneity of cancer cells and the high cost and risk associated with single-target therapies persist. The paper addresses the need for more effective and broadly applicable immunotherapies by investigating the potential of using induced pluripotent stem cells (iPSCs) derived from T-ALL patients. The rationale is that these iPSCs might share a common antigen profile with T-ALL cells, making them a suitable source for generating a comprehensive tumor antigen vaccine.

Methods

The researchers employed a multi-faceted approach to evaluate their T-ALL-iPSC-based immunotherapy:

  • iPSC Generation and Characterization: T-ALL patient-derived iPSCs (W10-iPSCs) were generated and characterized using standard techniques like alkaline phosphatase (AP) staining, immunofluorescence staining for pluripotency markers (SOX2, SSEA4, POU5F1, NANOG), and flow cytometry.
  • Antigen Preparation: Complete antigens were extracted from W10-iPSCs by repeated freeze-thaw cycles.
  • Dendritic Cell (DC) and T Cell Priming: Dendritic cells (DCs) and T cells were isolated from healthy donors. DCs were loaded with the T-ALL-iPSC antigens and then co-cultured with T cells to create antigen-specific cytotoxic T lymphocytes (CTLs), referred to as W10-DC-T cells.
  • In Vivo Studies:
    • Teratoma Formation Assay: To confirm the pluripotency of T-ALL iPSCs, they were injected into immunocompromised mice (NOD/SCID) and teratoma formation was assessed via histological analysis (HE staining).
  • T-ALL Mouse Model: A T-ALL mouse model was established by injecting Jurkat-GFP cells (a T-ALL cell line) into NOD/SCID mice. These mice were then treated with W10-DC-T cells.
  • Safety Evaluation: * Acute Toxicity: Assessed by monitoring body weight, and evaluating liver and kidney function through plasma levels of ALT, AST, albumin, creatinine (CRE), and blood urea nitrogen (BUN). Histological analysis of liver tissue was also performed.
  • Long-Term Toxicity: Evaluated by monitoring body weight over an extended period (23 days) and assessing organ weight ratios.
  • Antitumor Efficacy: Assessed by monitoring tumor progression (using Jurkat-GFP cells), disease severity scores, and survival rates of the treated mice.
  • In Vivo Distribution: The distribution of labeled W10-DC-T cells in mice was tracked using in vivo imaging.
  • Cytokine Release and T Cell Aging: Levels of inflammatory cytokines (IL-6, TNF-α) and markers of T cell aging (CD57, TIM3) were measured in the peripheral blood of treated mice.
  • Statistical Analysis: Data were analyzed using one-way ANOVA with p < 0.05 considered statistically significant.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • iPSCs as a Universal Tumor Antigen Source: The study strongly supports the idea that iPSCs derived from cancer cells can serve as a valuable and potentially universal source of tumor antigens for immunotherapy, bypassing the need to isolate primary tumor cells.
  • T-ALL-iPSC Antigens Elicit Potent Immune Responses: The W10-DC-T cells, loaded with antigens from T-ALL-derived iPSCs, demonstrated significant antitumor efficacy in a T-ALL mouse model, effectively reducing tumor burden and slowing disease progression.
  • Safety Profile is Promising: A critical finding is the lack of significant acute or long-term toxicity associated with the W10-DC-T cell therapy. This is crucial for the clinical translation of any new cancer treatment.
  • T-ALL-iPSCs Mimic T-ALL Cell Lines: The study builds upon previous work showing that W10-iPSCs share a gene expression profile similar to T-ALL cell lines, providing a strong rationale for their use in targeting T-ALL.
  • Immune Cell Aging as a Trade-off: While effective, the therapy was associated with increased expression of T cell aging markers (CD57, TIM3) and elevated inflammatory cytokines. This suggests a potential trade-off between efficacy and T cell exhaustion, which warrants further investigation.

Key Results

  • Tumor Inhibition: W10-DC-T cell treatment significantly reduced Jurkat-GFP tumor cell burden in NOD/SCID mice.
  • Survival Benefit: Treatment with W10-DC-T cells prolonged the survival of tumor-bearing mice.
  • No Acute Toxicity: No significant differences were observed in body weight, liver function (ALT, AST), or kidney function (CRE, BUN) between treated and control groups, indicating no acute toxicity.
  • No Medium/Long-Term Toxicity: Body weight remained stable in treated groups (except for the untreated tumor group), and organ weight ratios were normalized or showed improvements compared to tumor burden effects.
  • Cytokine Release and T Cell Aging: Elevated levels of IL-6 and TNF-α were observed, along with increased percentages of CD57+ and TIM3+ T cells in the W10-DC-T treated group, suggesting immune activation and potential T cell aging.

Limitations and Future Work

The authors acknowledge several limitations:

  • Antigen Profile Narrowness: Compared to complete primary tumor cell antigens, the antigens from single-cell-derived W10-iPSCs might have a narrower profile, which could impact efficacy against the full spectrum of hematologic malignancies.
  • Long-Term Toxicity Uncertainty: While no medium or long-term toxicity was observed in this study, the possibility of delayed-onset toxicity remains, as seen in other T cell therapies.
  • T Cell Aging and Exhaustion: The observed T cell aging and exhaustion suggest that strategies to reactivate T cells and improve immune responses may be necessary for sustained therapeutic benefit.
  • Optimal Dosage: The optimal administration dosage needs to be precisely determined.

Future work should focus on addressing these limitations, particularly by investigating the optimal dosage, exploring strategies to mitigate T cell aging and exhaustion, and evaluating the potential for delayed-onset toxicity. Further studies are also needed to assess the efficacy of this approach in human patients with T-ALL.

Summary updated

Abstract

T-ALL-iPSC-based treatment is safe and can be used as a potential strategy for leukemia immunotherapy.
BibTeX
@inproceedings{li2023evaluation,
  author = {Weiran Li and Meiling Zhou and Lu Wang and Liying Huang and Xuemei Chen and Xizhuo Sun and Tao Liu},
  title = {{Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T‐ALL‐iPSC in vivo}},
  booktitle = {Cancer},
  year = {2023},
  doi = {10.1002/cai2.95},
}
Figure